HER2 Testing in Breast Cancer

(based on 96 customer ratings)

Author: Kathryn R. Perkinson, BS, HTL(ASCP)
Reviewers: Carla Shoffeitt, MSM, HT(ASCP) and Erika Caceres, BS, HTL(ASCP)

HER2/neu is a useful tumor marker for therapeutic decision making in patients with breast cancer. This course includes a review current breast cancer statistics, a comparison of methods used for HER2/neu testing, proper interpretation of HER2/neu fluorescence in situ hybridization (FISH), and the College of American Pathologists (CAP) guidelines for HER2/neu FISH testing.

Continuing Education Credits

Objectives

  • Review current breast cancer statistics.
  • Compare methods for HER2 testing.
  • Explain the College of American Pathologists (CAP) guidelines for HER2 fluorescence in situ hybridization (FISH) testing.
  • Outline the method for HER2 FISH assay.
  • Demonstrate proper interpretation of HER2 FISH assay.

Course Outline

  • Introduction
      • Overview
  • Theoretical Background
      • HER2: The Protein and the Gene
      • HER2 Protein Overexpression and Gene Amplification
      • True or False: HER2 is overexpressed in over 50% of breast tumors.
      • True or False: HER2 is a member of the epidermal growth factor receptor (EGFR) family of oncogenes.
      • True or False: HER2 is located on the long arm of chromosome 20.
  • Clinical Utility of HER2/neu Testing
      • Clinical Utility of HER2 Testing
      • Trastuzumab
      • Trastuzumab: Additional Information
      • Testing for HER2: Sensitivity versus Specificity
      • True or False: Herceptin® is a drug that is used to treat patients with HER2-positive breast tumors.
      • True or False: Herceptin® is associated with low cost and cardiac toxicity.
      • Herceptin® (Trastuzumab) Response
  • Clinical Testing for HER2/neu
      • Testing Methodologies
      • History of Testing for HER2: Timeline
      • History of Testing for HER2: Early Trials Used Immunohistochemistry Testing
      • Testing Algorithms
      • HER2 by Immunohistochemistry
      • HER2 by In Situ Hybridization Methods
      • Additional Testing Methods for HER2
  • Methods to Assess HER2/neu Status
      • Fluorescence in Situ Hybridization versus Immunohistochemistry
      • Which of the following are the two primary methods used to assess HER2 status in clinical laboratories?
      • What are the benefits of using immunohistochemistry (IHC) as a marker for HER2 gene amplification?
  • Immunohistochemical Methods
      • Summary of HER2 Immunohistochemical Method
      • Patients with Immunohistochemistry 2+ Tumors
      • Interpretation of HER2 Immunohistochemistry
      • Interpretation of HER2 Immunohistochemistry: Agilent Dako HercepTest™
  • Fluorescence in Situ Hybridization Testing
      • Fluorescence In Situ Hybridization
      • Fluorescence In Situ Hybridization: Definitions
      • Need for Hematoxylin and Eosin Slide
      • Breast Cancer Sample: Normal for HER2 Gene Copy Number
      • Polysomy of Chromosome 17 in Breast Cancer
      • HER2 Fluorescence in Situ Hybridization Slide: Positive for Gene Amplification
      • HER2 Fluorescence in Situ Hybridization Interpretation
      • Fluorescence in Situ Hybridization: Equivocal Results
      • Test Systems Without a Chromosome 17 Centromere Signal to Enumerate
      • True or False: FISH staining results with an average HER2 signals/tumor cell of ≥4.0 and <6.0 with the HER2/CEP17 ratio of <2.0 are consid...
  • Testing Inaccuracies: Discordant Results Between IHC and FISH
      • Discordant Results Between Immunohistochemistry and Fluorescence in Situ Hybridization
      • Test Inaccuracies
      • Pre-Examination Causes of Test Inaccuracies
      • Examination Causes of Test Inaccuracies
      • Use of Image Analysis to Reduce Examination Phase Testing Inaccuracies
      • Post-Examination Causes of Test Inaccuracies
      • True or False: HER2 immunohistochemistry (IHC) scores of 1+, 2+, and 3+ are all considered positive for HER2.
  • HER2/neu Testing Guidelines
      • College of American Pathologists' Guidelines for HER2
      • Pre-Examination Guidelines: Specimen Handling Requirements
      • Examination Guidelines: Assays
      • Examination Guidelines: Interpretation
      • Post-Examination Guideline: Pathologist Competency
      • Quality Management
      • Validation Criteria
      • What is the Gold Standard?
      • True or False: Fluorescence in situ hybridization (FISH) is the gold standard for HER2 testing.
      • Which of the following is the range for optimal fixation times for HER2 FISH testing?
  • References
      • References

Additional Information

Level of Instruction: Basic to intermediate
Intended Audience:  Histotechnologists, histotechnicians, pathology assistants, and other medical laboratory personnel interested in this subject matter. This course is also appropriate for histology and medical laboratory science students, pathology residents, and practicing pathologists.  
Author Information: Kathryn R. Perkinson, BS, HTL(ASCP), has been the manager of the Molecular Pathology Department of Duke University Health System in Durham, North Carolina, since 1998.  She holds a Bachelor of Science in biochemistry from North Carolina State University. Kathryn has over 25 years of experience in molecular biology in both the research and clinical healthcare fields at Duke University. The Molecular Pathology Department, under her leadership, has tripled in size over the past 15 years. 
The author has no conflict of interest to disclose. 
Reviewer Information
Carla J. Shoffeitt, MSM, HT(ASCP), is the Manager of the Pathology Department of Emory St. Joseph’s Hospital of Emory Healthcare in Atlanta, Georgia. She holds a Master of Science Degree in Healthcare Management and a Bachelor of Science in Biology from Troy University, Troy, Alabama. She is certified as a Histotechnician and has 25 years of experience in the field of Histology.
Erika Caceres, BS, HTL(ASCP), has nearly eight years of experience as a histotechnologist, progressing from bench technician to pathology supervisor. She has expertise in tissue preparation, staining, and advanced histological techniques, including immunohistochemistry. Her leadership roles at Atrium Health involved directing workflow, optimizing antibodies, and ensuring compliance with CAP and CLIA regulations. She earned a Bachelor of Science in Biology from Queens University of Charlotte, where she focused on microbiology and cell biology, followed by completing her Histotechnology training at Carolinas College of Health Sciences.
Course Description: HER2 is a useful tumor marker for therapeutic decision-making in patients with breast cancer. This course includes a review of current breast cancer statistics and compares various methods for HER2 testing. Information is based on the ASCO/CAP HER2 Test Guide.

This course is part of:
her2 slide 22
her2 pg 61
her2 pg 62
her2 pg 64
HER2 testing timeline